Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

NIDA CTN-0152: Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder: A Pragmatic, Multi-site, Double-blind, Randomized, Placebo-controlled Trial (TAB)

NCT06651177 is registered in ClinicalTrials.gov with T. John Winhusen, PhD as lead sponsor.

NCT NCT06651177
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06651177 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
NIDA CTN-0152: Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder: A Pragmatic, Multi-site, Double-blind, Randomized, Placebo-controlled Trial (TAB)
Lead sponsor
T. John Winhusen, PhD
Phase
Phase 2
Overall status
Recruiting
Start date
January 29, 2026
Completion date
October 31, 2027
Enrollment
310 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

opioid use disorder, opioid use disorder, moderate, opioid use disorder, severe